• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form D filed by Adagio Medical Holdings Inc

    10/29/25 4:10:01 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care
    Get the next $ADGM alert in real time by email
    SEC FORM D

    The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
    The reader should not assume that the information is accurate and complete.

    UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM D

    Notice of Exempt Offering of Securities

    OMB APPROVAL
    OMB Number: 3235-0076
    Estimated average burden
    hours per response: 4.00

    1. Issuer's Identity

    CIK (Filer ID Number) Previous Names
       None
    Entity Type
    0002006986
    Aja Holdco, Inc.
    X Corporation
       Limited Partnership
       Limited Liability Company
       General Partnership
       Business Trust
       Other (Specify)

    Name of Issuer
    Adagio Medical Holdings, Inc.
    Jurisdiction of Incorporation/Organization
    DELAWARE
    Year of Incorporation/Organization
    X Over Five Years Ago
       Within Last Five Years (Specify Year)
       Yet to Be Formed

    2. Principal Place of Business and Contact Information

    Name of Issuer
    Adagio Medical Holdings, Inc.
    Street Address 1 Street Address 2
    26051 MERIT CIRCLE SUITE 102
    City State/Province/Country ZIP/PostalCode Phone Number of Issuer
    LAGUNA HILLS CALIFORNIA 92653 (949) 348-1188

    3. Related Persons

    Last Name First Name Middle Name
    Usen Todd
    Street Address 1 Street Address 2
    c/o Adagio Medical Holdings, Inc. 26051 Merit Circle, Suite 102
    City State/Province/Country ZIP/PostalCode
    Laguna Hills CALIFORNIA 92653
    Relationship: X Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Kaster Deborah
    Street Address 1 Street Address 2
    c/o Adagio Medical Holdings, Inc. 26051 Merit Circle, Suite 102
    City State/Province/Country ZIP/PostalCode
    Laguna Hills CALIFORNIA 92653
    Relationship: X Executive Officer    Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Mishan Orly
    Street Address 1 Street Address 2
    c/o Adagio Medical Holdings, Inc. 26051 Merit Circle, Suite 102
    City State/Province/Country ZIP/PostalCode
    Laguna Hills CALIFORNIA 92653
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Cox James L.
    Street Address 1 Street Address 2
    c/o Adagio Medical Holdings, Inc. 26051 Merit Circle, Suite 102
    City State/Province/Country ZIP/PostalCode
    Laguna Hills CALIFORNIA 92653
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Moran Timothy P.
    Street Address 1 Street Address 2
    c/o Adagio Medical Holdings, Inc. 26051 Merit Circle, Suite 102
    City State/Province/Country ZIP/PostalCode
    Laguna Hills CALIFORNIA 92653
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Gardiner Sandra
    Street Address 1 Street Address 2
    c/o Adagio Medical Holdings, Inc. 26051 Merit Circle, Suite 102
    City State/Province/Country ZIP/PostalCode
    Laguna Hills CALIFORNIA 92653
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    Last Name First Name Middle Name
    Mirsaeedi-Farahani Keyvan
    Street Address 1 Street Address 2
    c/o Adagio Medical Holdings, Inc. 26051 Merit Circle, Suite 102
    City State/Province/Country ZIP/PostalCode
    Laguna Hills CALIFORNIA 92653
    Relationship:    Executive Officer X Director    Promoter

    Clarification of Response (if Necessary):


    4. Industry Group

       Agriculture
    Banking & Financial Services
       Commercial Banking
       Insurance
       Investing
       Investment Banking
       Pooled Investment Fund
    Is the issuer registered as
    an investment company under
    the Investment Company
    Act of 1940?
       Yes    No
       Other Banking & Financial Services
       Business Services
    Energy
       Coal Mining
       Electric Utilities
       Energy Conservation
       Environmental Services
       Oil & Gas
       Other Energy
    Health Care
       Biotechnology
       Health Insurance
       Hospitals & Physicians
       Pharmaceuticals
    X Other Health Care
       Manufacturing
    Real Estate
       Commercial
       Construction
       REITS & Finance
       Residential
       Other Real Estate
      
    Retailing
      
    Restaurants
    Technology
       Computers
       Telecommunications
       Other Technology
    Travel
       Airlines & Airports
       Lodging & Conventions
       Tourism & Travel Services
       Other Travel
      
    Other

    5. Issuer Size

    Revenue Range OR Aggregate Net Asset Value Range
       No Revenues    No Aggregate Net Asset Value
       $1 - $1,000,000    $1 - $5,000,000
       $1,000,001 - $5,000,000    $5,000,001 - $25,000,000
       $5,000,001 - $25,000,000    $25,000,001 - $50,000,000
       $25,000,001 - $100,000,000    $50,000,001 - $100,000,000
       Over $100,000,000    Over $100,000,000
    X Decline to Disclose    Decline to Disclose
       Not Applicable    Not Applicable

    6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

       Rule 504(b)(1) (not (i), (ii) or (iii))
       Rule 504 (b)(1)(i)
       Rule 504 (b)(1)(ii)
       Rule 504 (b)(1)(iii)
    X Rule 506(b)
       Rule 506(c)
       Securities Act Section 4(a)(5)
       Investment Company Act Section 3(c)
       Section 3(c)(1)    Section 3(c)(9)  
       Section 3(c)(2)    Section 3(c)(10)
       Section 3(c)(3)    Section 3(c)(11)
       Section 3(c)(4)    Section 3(c)(12)
       Section 3(c)(5)    Section 3(c)(13)
       Section 3(c)(6)    Section 3(c)(14)
       Section 3(c)(7)

    7. Type of Filing

    X New Notice Date of First Sale 2025-10-17    First Sale Yet to Occur
       Amendment

    8. Duration of Offering

    Does the Issuer intend this offering to last more than one year?
       Yes X No

    9. Type(s) of Securities Offered (select all that apply)

    X Equity    Pooled Investment Fund Interests
       Debt    Tenant-in-Common Securities
    X Option, Warrant or Other Right to Acquire Another Security    Mineral Property Securities
    X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security    Other (describe)

    10. Business Combination Transaction

    Is this offering being made in connection with a business combination transaction, such as a merger, acquisition or exchange offer?
       Yes X No

    Clarification of Response (if Necessary):

    11. Minimum Investment

    Minimum investment accepted from any outside investor $0 USD

    12. Sales Compensation

    Recipient
    Recipient CRD Number    None
    Piper Sandler & Co. 665
    (Associated) Broker or Dealer X None
    (Associated) Broker or Dealer CRD Number X None
    None None
    Street Address 1 Street Address 2
    1251 Avenue of the Americas, 6th Floor
    City State/Province/Country ZIP/Postal Code
    New York NEW YORK 10020
    State(s) of Solicitation (select all that apply)
    Check “All States” or check individual States
       All States
       Foreign/non-US
    CALIFORNIA
    COLORADO
    CONNECTICUT
    FLORIDA
    GEORGIA
    ILLINOIS
    MARYLAND
    MASSACHUSETTS
    NEW YORK
    PENNSYLVANIA
    TEXAS
    UTAH
    WASHINGTON
    WISCONSIN

    13. Offering and Sales Amounts

    Total Offering Amount $49,846,793 USD
    or    Indefinite
    Total Amount Sold $18,999,999 USD
    Total Remaining to be Sold $30,846,794 USD
    or    Indefinite

    Clarification of Response (if Necessary):

    Total offering amount assumes exercise of all pre-funded and tranche warrants. Amount remaining to be sold reflects aggregate exercise price of warrants

    14. Investors

      
    Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering.
    Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:
    16

    15. Sales Commissions & Finder's Fees Expenses

    Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

    Sales Commissions $0 USD
       Estimate
    Finders' Fees $1,245,000 USD
       Estimate

    Clarification of Response (if Necessary):

    16. Use of Proceeds

    Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

    $0 USD
       Estimate

    Clarification of Response (if Necessary):

    Proceeds are for working capital. The number above excludes use of proceeds for normal salary and bonus to executive officers.

    Signature and Submission

    Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

    Terms of Submission

    In submitting this notice, each issuer named above is:
    • Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
    • Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of:  (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
    • Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Rule 504 or Rule 506 for one of the reasons stated in Rule 504(b)(3) or Rule 506(d).

    Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

    For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

    Issuer Signature Name of Signer Title Date
    Adagio Medical Holdings, Inc. /s/ Deborah Kaster Deborah Kaster Chief Financial Officer and Chief Business Officer 2025-10-29

    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

    * This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.


    Get the next $ADGM alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ADGM

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ADGM
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical to Present at the Piper Sandler 37th Annual Healthcare Conference

    Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced that management will be presenting at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:30 a.m. ET at the Lotte Palace in New York, NY. Presentation Information A live and recorded webcast of the presentation will be available at: https://event.webcasts.com/starthere.jsp?ei=1742138&tp_key=f2a06e9abc About Adagio Medical Holdings, Inc. Adagio is a medical device company focused on developing and commercializing products for the treatment of cardiac arrhythmias utilizi

    11/5/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Closes Financing of $19 Million Upfront; Positions Company to Advance Purpose-Built Technology for Treatment of Ventricular Tachycardia

    Proceeds Expected to Fund Ongoing Development and Submission Activities to Support FDA Evaluation of Company's First and Next Generation Proprietary Ultralow Cryoablation Technologies Adagio Medical Holdings, Inc. (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced the closing of its previously announced private placement (https://investors.adagiomedical.com/news-releases/news-release-details/adagio-medical-announces-pricing-50-million-private-placement), led by existing investors and new healthcare-dedicated institutional investors. Adagio intends to deploy the net proceeds to: Sup

    10/20/25 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Perceptive Advisors Llc

    4 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    10/22/25 4:33:15 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Kaster Deborah

    3 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    9/30/25 6:01:40 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider George Dan

    3 - Adagio Medical Holdings, Inc. (0002006986) (Issuer)

    4/28/25 5:23:28 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Adagio Medical Holdings Inc

    SCHEDULE 13G/A - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    11/13/25 9:04:35 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Adagio Medical Holdings Inc

    424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    11/12/25 4:10:28 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form 424B3 filed by Adagio Medical Holdings Inc

    424B3 - Adagio Medical Holdings, Inc. (0002006986) (Filer)

    11/12/25 4:11:37 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Leadership Updates

    Live Leadership Updates

    View All

    Adagio Medical Reports Third Quarter 2025 Results

    Continued Momentum Toward PMA Submission of ULTC Technologies Recent Financing Positions Company to Execute Growth Strategy Adagio Medical Holdings, Inc (NASDAQ:ADGM) ("Adagio" or "the Company"), a leading innovator in catheter ablation technologies for the treatment of cardiac arrhythmias, today announced financial results for the third quarter ended September 30, 2025. Recent Business Highlights: Closed a private placement on October 20, 2025, with gross proceeds of up to $50 million, led by a syndicate of healthcare-dedicated institutional investors; upfront proceeds of approximately $19 million expected to fund FDA submission activities and ongoing next generation catheter deve

    11/12/25 4:05:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Appoints Deborah Kaster as Chief Business Officer

    Adagio Medical (NASDAQ:ADGM), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, is pleased to announce the appointment of Deborah Kaster as Chief Business Officer (CBO). Kaster brings more than 25 years of leadership experience in strategy, mergers and acquisitions, corporate finance, investor relations and strategic communications in the medical technology sector. Most recently, Kaster served as Vice President of Investor Relations at Shockwave Medical, where she played a pivotal role in the company's growth from IPO to its acquisition by Johnson & Johnson. During her time at Shockwave, the company's stock price appreciated nearly 2000%, a testame

    3/31/25 4:01:00 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    Adagio Medical Announces Appointment of Accomplished Medical Device Leader Todd Usen as Chief Executive Officer and Director

    Founding Chief Executive Officer and Director Olav Bergheim to Depart Adagio Medical Holdings, Inc. (NASDAQ:ADGM, the "Company" or "Adagio")), a leading innovator in catheter ablation technologies for treatment of cardiac arrhythmias, today announced that founder Olav Bergheim departed as Chief Executive Officer ("CEO") and Chairperson of the Board of Directors of the Company, effective December 13, 2024. Concurrently, the Company announced the appointment of Todd Usen, as Chief Executive Officer and Director of the Company and Orly Mishan, as Chairperson of the Board of Directors, effective December 13, 2024. Mr. Bergheim will serve as an advisor to the Company and will support Mr. Usen

    12/16/24 8:00:00 AM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    $ADGM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    11/13/24 4:30:17 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Adagio Medical Holdings Inc

    SC 13G - Adagio Medical Holdings, Inc. (0002006986) (Subject)

    8/12/24 4:22:57 PM ET
    $ADGM
    Medical/Dental Instruments
    Health Care